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Abstract The majority of mutations in the human phenylala-
nine hydroxylase (PAH) gene that lead to the recessive disease
phenylketonuria (PKU) are believed to affect the activity or
stability of the PAH enzyme. In this study we have performed in
vivo analyses of lymphocyte PAH mRNA from PKU patients
homozygous for the PKU missense mutations P281L and R408Q
as well as the nonsense mutations G272X and Y356X. The
mutations G272X, P281L and R408Q, which are located outside
the consensus splice site sequence, result in transcripts with one
or more exons skipped in addition to full-length transcripts. The
mutation Y356X results in transcripts with one or more exons
skipped, but no full-length transcripts. Our findings question the
value of functional and structural predictions of mutations at the
protein level without analyses of the corresponding transcript.
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1. Introduction
Phenylketonuria (PKU) is an autosomal recessive human
genetic disorder caused by the absence or severe reduction
of phenylalanine hydroxylation. At present, more than 290
mutations associated with PKU have been reported in the
hepatically expressed human phenylalanine hydroxylase gene
(hPAH) [1]. Among these PKU mutations more than 60% are
classi¢ed as missense mutations within the protein coding part
of the gene, while 11% are classi¢ed as splice mutations based
on changes in the 5P or 3P consensus splice site. However, at
least for a few percent of the missense mutations, a splice
defect may be predicted based on the creation of a new 5P
or 3P consensus splice site [2].
In vitro protein expression analyses have shown that PKU
mutations may result in complete loss of enzyme activity,
increased protein turnover or abnormal kinetics of the enzyme
(for a review see [1]).
However, some mutant PAH proteins show a residual en-
zymatic activity too high to explain the PKU phenotype of
patients with these mutations. Also, the e¡ect of some muta-
tions in the PAH gene has been predicted from 3D computer
modelling of the structure of the PAH enzyme [3]. However,
all these analyses are based on predictions of amino acid
substitutions in the PAH protein without any in vivo evidence
for the existence of single base substituted transcripts encod-
ing these proteins.
Previously, we have shown that an ACG mutation at
cDNA position 611 in exon 6 of the hPAH gene, believed
to cause the amino acid substitution Y204C, leads to the
creation of a new, functionally active 5P donor splice site [2].
In this work we expanded the study on missense and stop
mutations by in vivo mRNA analyses of four exonic point
mutations in samples from homozygous patients. The experi-
ments had to be carried out on transcripts of the hPAH gene
from cultured lymphocytes of PKU patients, as hepatic
mRNA from PKU patients is not accessible. We found that
the four mutations, which lie outside normally considered
splice site consensus sequences, all lead to abnormal splicing
of the hPAH mRNA.
2. Materials and methods
2.1. Patients
The genotypes and phenotypes of PKU patients (Table 1) have
previously been described [4]. The patient homozygous for the
R408Q mutation had a mild PKU phenotype (823 WM pre-treatment
serum phenylalanine), while the patients homozygous for the P281L,
G272X and Y356X mutations, respectively, had the classical metabol-
ic phenotype of PKU (s 1200 WM phenylalanine).
2.2. RT-PCR
Isolation of illegitimately transcribed hPAH mRNA from cultured
lymphocytes (ectopic transcripts) of the PKU patients, cDNA syn-
thesis and nested PCR were performed as previously described [2].
In addition, PCR primers used for a second round of PCR were
5P-GATCCTGTGTACCGTGCAAG-3P (forward, cDNA positions
451^470) and 5P-CTCCATCAACAGATTCACAGC-3P (reverse,
cDNA positions 1386^1406)). RT-PCR on a normally spliced hPAH
mRNA using these conditions ampli¢ed a full-length PCR product of
957 bp. RT-PCR products were visualized in UV light after electro-
phoresis in 1.5% or 2% agarose gels and ethidium bromide (EtBr)
staining. RT-PCR products were measured by the intensity of EtBr
£uorescence in UV light (GDS 8000 System, UVP Ltd., Cambridge,
UK). cDNA sequencing was performed on both strands as previously
described [2] applying the same primers as for the second round of
PCR.
3. Results
Blood samples from patients homozygous for the mutations
P281L, R408Q, G272X and Y356X were cultured. mRNA
was subsequently extracted and analyzed by RT-PCR as de-
scribed.
RT-PCR ampli¢cation of mRNA isolated from normal
blood donors produced exclusively a 957 bp product from
the 3P end of the hPAH coding region, corresponding to
cDNA positions 451^1406 (exon 5^5P UTR), representing
the normally spliced 3P end of hPAH mRNA (con¢rmed by
DNA sequencing) (Fig. 1A^C).
Two fragments were ampli¢ed from lymphocyte mRNA
isolated from the patient homozygous for the P281L mutation
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(Fig. 1A). DNA sequencing showed that the largest fragment
represented a full-length transcript while the smaller repre-
sented a transcript with exon 8 deleted. Both mutant frag-
ments contained the 842CCT mutation (P281L) of exon 7
found in the genomic DNA from this patient. The shortest
transcript represents a double mutant transcript from a single
allele (P281L/vexon 8).
The RT-PCR analysis of the patient homozygous for the
R408Q mutation revealed three di¡erently sized fragments
(Fig. 1C). In addition to the full-length transcript (normally
spliced transcript) with the 1223GCA mutation, the two
shorter fragments had deletions of exon 12 and exons 8^12
in the transcripts, respectively.
The RT-PCR products ampli¢ed from mRNA from the
patient homozygous for the G272X mutation were the full-
length transcript with the 814GCT mutation, as well as a
vexon 7 transcript (Fig. 1A). Analysis of the patient homo-
zygous for the Y356X mutation revealed two di¡erently
spliced transcripts lacking exon 11 and exons 8^11, respec-
tively (Figs. 1B and 2). No full-length transcript was ampli¢ed
from lymphocyte mRNA from this patient.
All the exon skipping observed predicts frame-shifts and
premature stop codons in translation, except for the vexon
8^11 transcript in the patient homozygous for Y356X. This
transcript predicts a protein with an internal deletion. The
skipping of exons 8^11 preserves the original reading frame,
but results in a new codon made up of the last two nucleotides
in exon 7 and the ¢rst nucleotide in exon 12 (CCG, Pro).
All results were con¢rmed by duplicate experiments.
Fig. 1. A^C: RT-PCR analysis of lymphocyte mRNA from homo-
zygous PKU patients. PCR ampli¢cation using mRNA samples iso-
lated from cultured lymphocytes from normal blood donors (N)
and PKU patients homozygous for the G272X and P281L muta-
tions (A), Y356X mutation (B) and R408Q mutation (C). PCR
products were separated on 2% agarose gels and stained with EtBr.
f.l., full-length PCR product.
Fig. 2. DNA sequence of the two transcripts found in lymphocytes
isolated from a patient homozygous for the Y356X mutation.
A: Transcript with exon 11 deleted. B: Transcript with exons 8^11
deleted.
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4. Discussion
The predicted mutant PAH proteins previously reported for
mutations G272X, P281L and R408Q have been functionally
analyzed in several in vitro protein expression systems [1].
These analyses have focused on the e¡ect of the amino acid
substitution predicted from the mutation detected in genomic
DNA, without looking for the existence of a mutant transcript
encoding these mutant proteins.
R408Q is associated with a mild PKU phenotype, but the
hPAH residual activity of s 50% [5] is in contradiction with a
PKU diagnosis. However, the level of residual PAH activity
needed to correct a PKU phenotype is still unclear. The par-
tial exon skipping described here, resulting in transcripts en-
coding non-functional PAH proteins, might be the additional
mechanism necessary to explain that the R408Q mutation is
associated with a PKU phenotype.
Repeated ampli¢cations of transcripts from non-PKU indi-
viduals (normal alleles) did not reveal any aberrantly spliced
RT-PCR products. This suggests that the abnormally spliced
transcripts observed are a consequence of the mutations
studied in this work.
Liver biopsies can normally not be collected from PKU
patients, and our studies are restricted to illegitimately tran-
scribed mRNA isolated from cultured lymphocytes. However,
the transcripts from the splice mutation IVS 12 nt1g/a muta-
tion was studied both in liver [6] and in cultured lymphocytes
[2] and the mutation caused aberrant splicing in both types of
cells.
The relative amounts of di¡erent transcripts within a sam-
ple were determined (Table 1) based on the principles of al-
lele-speci¢c quanti¢cation [7]. The data represent a rough
quanti¢cation and documents that there is a di¡erence in
the expression level or mRNA stability between the di¡erently
spliced forms of PAH caused by a single mutation (Fig. 1,
Table 1). However, mRNA from human liver should be used
for a more precise quanti¢cation of the expression level/stabil-
ity of the di¡erently spliced forms of PAH.
Several hypotheses have been proposed to explain exon
skipping. A change in the secondary mRNA structure, with
consequent aberrations in splicing, has been suggested in sev-
eral studies [8^10]. Recognition of a nonsense codon prior to
splicing, with the subsequent skipping of the mutant exon in
order to preserve an open reading frame, has also been pro-
posed [11]. In addition, preservation of the open reading
frame by exon skipping has been shown for other types of
exonic mutations [12].
Exon enhancers and purine-rich exon splicing elements are
strong sequence signals within exons that promote splicing,
and several studies that identi¢ed such sequence motifs have
shown that exon skipping can be caused by mutating these
sequences [13,14]. Recently, several reports speculate that the
observed exon skipping associated with nonsense mutations
may very well be the result of disrupting such exonic sequen-
ces relevant for the splicing process [15,16]. In fact, this has
been shown for a nonsense mutation in the dystrophin gene,
where a G to T transversion resulting in partial exon skipping
was shown by in vitro studies to disrupt the function of a
splicing enhancer sequence [17].
For all of the studied mutations, except for the Y356X
mutation, both the full-length transcripts containing the mu-
tation and transcripts with skipped exons were found. This
suggests that these mutations create new splice sites/informa-
tion to a variable degree and that the molecular basis of PKU
caused by these mutations is complex.
Recently Erlandsen et al. [3] reported the 3D structure of
the human PAH enzyme. By 3D computer modelling, they
explained the molecular mechanisms of the enzymatic pheno-
types in PKU/HPA patients. However, in this study we have
demonstrated that the molecular basis of the PKU disease is
complex, and that exonic mutations generally believed to only
a¡ect the PAH protein also cause aberrant RNA processing.
If aberrant transcripts are a frequent consequence of exonic
point mutations, a re-examination of a large number of dis-
ease-related mutations, with mechanisms we thought to be
known, is required. This may explain some of the missing
correlation between genotype and phenotype observed for
many mutations in genetic diseases.
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